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miRNA – microRNA 
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CFU – colony forming unit 
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Mycobacterium tuberculosis (Mtb), the main causative agent of tuberculosis, is among the 
world’s most ancient and most successful pathogens. Its success can be attributed to its ability 
to avoid phagosomal destruction, survive and proliferate inside its host cells, of which the most 
important are the human macrophages. Besides being able to block phagosome-lysosome 
fusion, Mtb is able to inhibit the expression of lysosomal hydrolases, such as cathepsins. 
Cathepsins are a major class of lysosomal enzymes which have various functions. One in 
particular, cathepsin S, has been deeply implicated in peptide processing for antigen 
presentation, assuming in this way an important role in mediating the innate and adaptive 
immune responses to external invaders in the human body. In this work we analyzed a putative 
cathepsin gene regulation mechanism employed by Mtb, making use of miRNAs, small RNAs 
which post-transcriptionally regulate gene expression. 
The first part of this work was dedicated to unraveling the effect of Mtb in the expression of 
cathepsin S and the candidate regulator miRNA-106b-5p (miR-106b-5p) in the context of 
macrophage infection. We have determined that miR-106b-5p is up-regulated, while cathepsin 
S is down-regulated during Mtb infection of macrophages, in contrast with the non-pathogenic 
M. smegmatis which seems to have no effect in either.  
Bioinformatics data point out that the cathepsin S gene (CtsS) is a target for miR-106b-5p. 
As such, in the second part of this thesis we experimentally tested this hypothesis. First, the 
transfection of THP-1 cell line with miR-106b-5p mimics resulted in a decrease of cathepsin S, 
but not as exacerbated as we expected. The same effect has been reported for proteins that 
were shown to be very stable along time. Secondly, by using luciferase expression vectors and 
subsequent luciferase activity assays, we showed that the mRNA of CtsS is indeed a target for 
miR-106b-5p. Altogether, our results indicate that Mtb inhibits cathepsin S expression via miR-












A tuberculose é uma doença infecciosa que atormenta a humanidade desde há cerca de 
9000 anos. A partir do século XVII, com a industrialização da sociedade e a concentração das 
pessoas em áreas urbanas, a tuberculose atingiu proporções catastróficas e transformou-se 
num verdadeiro flagelo, tornando-se numa das principais causas de morte na Europa. Ao 
longo dos tempos foi ganhando diferentes nomes, tais como tísica pulmonar, ou peste branca. 
Por ser uma doença tão devastadora e não ter ainda uma cura nessa época, a tuberculose era 
frequentemente abrangida e descrita em obras de arte e literatura como uma força 
inescapável do destino, semelhante à própria Morte. Com a descoberta do agente etiológico 
da doença, bem como o aparecimento dos antibióticos e o melhoramento da higiene e 
condições sanitárias, a incidência e mortalidade atribuídas à tuberculose começaram a 
declinar, e a doença foi sendo mantida sob controlo durante o século XX. No entanto, em 
1992, a Organização Mundial de Saúde (OMS) declarou o ressurgimento da tuberculose como 
uma das doenças mais alarmantes a nível mundial: o surgimento e prevalência de estirpes 
com diversas formas de multi-resistência a antibióticos, e o consórcio oportunista entre o 
Mycobacterium tuberculosis e o vírus da imunodeficiência humana (VIH), foram as principais 
causas apontadas para este ressurgimento. Actualmente, a tuberculose é uma das doenças, 
associada a um agente patológico, que mais mortes causa no mundo; apenas em 2011, 8.7 
milhões de pessoas contraíram a doença e 1.4 milhões morreram da doença. 
O primeiro agente etiológico da tuberculose a ser descoberto, no século XIX, foi o 
Mycobacterium tuberculosis, um ser procariota pertencente ao filo Actinobacteria. Mais tarde, 
6 outras espécies do género Mycobacterium foram identificadas como igualmente capazes de 
causar a doença em humanos, e hoje integram um grupo designado por complexo 
Mycobacterium tuberculosis (CMTB); ainda assim, M. tuberculosis é o mais comum agente da 
doença a nível mundial. O género Mycobacterium, compreende maioritariamente espécies 
inofensivas e saprófitas, contendo apenas um pequeno número de espécies patogénicas, de 
entre as quais se pode listar M. leprae e M. ulcerans, agentes causadores da lepra e da úlcera 
de Buruli respectivamente, para além de M. tuberculosis.  
As micobactérias do CMTB estão entre os patogénios mais bem sucedidos do mundo. 
Grande parte deste sucesso pode atribuír-se à sua capacidade de conseguirem sobreviver 
dentro dos macrófagos humanos após terem sido fagocitadas. No processo geral de 
fagocitose em que o conteúdo internalizado é digerido, a maturação do fagossoma consiste 
numa série de fissões e fusões parciais do organelo com outros, em diferentes estádios de 
maturação com trocas parciais de componentes membranares e do lúmen. Estes fenómenos 
ocorrem durante o tráfego celular da periferia da célula até à região perinuclear onde existem 
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os lisossomas funcionais e ao longo de elementos do citoesqueleto. Durante o transporte o 
fagossoma vai maturando, isto é, torna-se competente para fundir com o lisossoma, fusão 
essa da qual resulta o fagolisossoma, vesícula que contém enzimas hidrolíticas num lúmen 
acidificado a pH aproximadamente igual a 5, ambiente que proporciona uma forte digestão dos 
seus conteúdos. O M. tuberculosis e espécies aparentadas conseguem bloquear a maturação 
do fagossoma e desse modo controlar o seu próprio destino intracelular; estão descritos 
diversos mecanismos através dos quais estas micobactérias conseguem subverter as etapas 
da fagocitose em seu favor, e também impedir a sua morte intracelular por apoptose do 
macrófago infectado, originando uma resposta imunitária exacerbada e desregulada que, em 
última análise, origina os próprios sintomas da doença. Porém, na maior parte dos casos, e 
tratando-se de indivíduos à partida saudáveis e imunocompetentes, o sistema imunitário é 
capaz de controlar a infecção, confinando as bactérias em estruturas histológicas pulmonares 
denominadas granulomas; deste modo, diz-se que há uma infecção latente, em que a bactéria 
está viva e dentro do organismo, mas não causa sintomas de doença. Vários factores, tanto 
fisiológicos como imunitários, podem então desencadear o desenvolvimento de tuberculose 
activa a partir de uma infecção latente, ou então fazer com que a infecção primária origine 
imediatamente uma situação de doença activa. 
A nível sub-celular, o lisossoma contém vários tipos de enzimas hidrolíticas, de entre as 
quais se destaca um grupo de proteases denominadas catepsinas. Estas hidrolases 
lisossomais não só actuam na degradação de proteínas e processamento de péptidos para 
apresentação de antigénios como contribuem para a remodelação da matriz extracelular e 
para a reabsorção óssea. A maior parte das catepsinas são proteases de cisteína (catepsinas 
B, C, F, H, K, L, O, S, V, X e W), sendo duas delas proteases de serina (catepsinas A e G) e 
outras duas proteases de aspartato (catepsinas D e E). 
Os microRNAs (miRNAs) são pequenas moléculas de RNA em cadeia simples, 
compostas por cerca de 22 nucleótidos, que possuem funções de regulação da expressão 
genética a nível pós-transcricional. Até há cerca de três décadas atrás, o Dogma Central da 
Biologia estava bem estabelecido: segundo este, DNA origina RNA, e RNA origina proteínas, 
atribuindo ao RNA um papel simples, intermediário e passivo. A descoberta dos primeiros 
miRNAs veio revolucionar esta visão e modernizar o pensamento científico em genética, 
introduzindo pela primeira vez o conceito de um tipo de RNA com funções regulatórias. A 
biogénese e maturação dos miRNAs é complexa, envolvendo várias etapas de processamento 
e modificação, desde que são transcritos do genoma até se tornarem maduros e funcionais. 
Os miRNAs maduros encontram-se associados ao complexo silenciador induzido por miRNA 
(miRISC), e é nesta forma que exercem a sua função: os miRNAs possuem afinidade para 
uma sequência de 7-8 nucleótidos contida na região não traduzida a 3’ (3’-UTR) do mRNA dos 
seus genes alvo, e ao se ligarem ao mRNA através desta sequência, por complementaridade 
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total ou parcial de bases, impedem que ele seja traduzido pelos ribossomas, provocando a 
sua degradação, ou destabilizando a sua estrutura molecular. 
O objectivo deste trabalho é investigar uma relação causal entre a infecção de 
macrófagos humanos por M. tuberculosis, miRNAs, e catepsinas. A catepsina S, uma 
protease de cisteína, tem sido fortemente implicada no processamento peptídico para 
apresentação de antigénios através do complexo principal de histocompatibilidade classe II 
(MHC-II); estudos anteriores já constataram a manipulação desta catepsina por 
Mycobacterium bovis Bacille Calmette-Guérin (BCG) em macrófagos, porém ainda nenhum 
estudo relacionado com a catepsina S foi feito em M. tuberculosis. Também, experiências 
preliminares evidenciaram que alguns miRNAs são diferencialmente expressos em 
macrófagos infectados com M. tuberculosis, entre os quais o miRNA-106b-5p (miR-106b-5p). 
Por análise bioinformática foi possível prever que o gene da catepsina S humana (CtsS) é um 
potencial alvo para o miR-106b-5p; deste modo, a hipótese de um modelo de regulação 
génica, durante a infecção, baseado na manipulação do miR-106b-5p e consequente 
alteração da expressão de CtsS, pode ser explorada. 
Na primeira parte do trabalho explorámos a existência ou não de associações entre M. 
tuberculosis e CtsS, e entre M. tuberculosis e o miR-106b-5p, no contexto da infecção. Numa 
triagem preliminar, usámos uma biblioteca de lentivírus para silenciar macrófagos, 
diferenciados a partir de células monocíticas da linha celular THP-1, para as diferentes 
catepsinas. As linhas celulares slenciadas para cada catepsina foram então infectadas com a 
espécie não patogénica M. smegmatis, e a sobrevivência intracelular das bactérias foi 
analisada através do método das unidades formadoras de colónias (CFUs). Os resultados 
mostram que várias catepsinas, incluindo a catepsina S, possuem um efeito bactericida 
induzindo a morte intracelular de M. smegmatis. De todas as catepsinas testadas procedemos 
a um estudo dirigido à função da catepsina S no contexto da infecção por um patogénio, o M. 
tuberculosis, e, no seguimento dos dados bioinformáticos que indicavam uma potencial 
regulação da catepsina S pelo miR-106b-5p, observámos que a expressão de catepsina S em 
macrófagos infectados com M. tuberculosis é marcadamente reduzida em comparação com 
macrófagos não infectados ou infectados com M. smegmatis. Estabelecemos ainda a relação 
com a expressão genética do miR-106b-5p que em macrófagos infectados com M. 
tuberculosis está claramente sobre-expresso, comparativamente com os infectados com M. 
smegmatis. Concluímos que os mecanismos de virulência do M. tuberculosis controlam o 
aumento na expressão genética do miR-106b-5p, acompanhado de uma redução da 
quantidade de proteína da catepsina S, durante a infecção em macrófagos humanos. 
Em seguida procurámos averiguar experimentalmente os dados bioinformáticos preditivos 
que obtivemos para o miR-106b-5p, ou seja, se o mRNA CtsS é realmente um alvo para este 
miRNA. Transfectámos macrófagos humanos com mimetizadores do miR-106b-5p para 
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exacerbar o efeito do miRNA e avaliar os efeitos na quantidade de catepsina S. Os resultados 
mostram uma redução na quantidade de proteína catepsina S em macrófagos transfectados 
com os mimetizadores que não é muito exacerbada, mas que existe; o mesmo tipo de efeito 
tem sido reportado quando as proteínas celulares são estáveis, não se esperando valores 
diferenciais maiores que 20%. De seguida demonstrámos o efeito do miR-106b-5p sobre o 
seu alvo putativo, o mRNA do gene CtsS. Para estas experiências foram usados vectores 
plasmídicos produtores de luciferase, dentro dos quais foi clonado um fragmento da 3’-UTR do 
gene CtsS contendo uma cópia da sequência alvo do miR-106b-5p; este fragmento foi inserido 
a jusante do gene da luciferase no vector, e desse modo, ao ser transcrito, o mRNA do gene 
da luciferase irá também conter o fragmento clonado. Os vectores recombinantes obtidos 
desta forma foram então transfectados para células da linha HEK 293T juntamente com 
mimetizadores do miR-106b-5p; posteriormente, estas células foram lisadas para ser realizado 
um ensaio de leitura da actividade da luciferase nestas condições. Os resultados que 
obtivemos indicam uma redução da actividade da luciferase na presença do mimetizador do 
miR-106b-5p, em comparação com o controlo em que se transfectou com o vector mas sem o 
mimetizador. Uma redução na actividade da luciferase nestas condições significa que o 
mimetizador bloqueou a tradução do mRNA do gene da luciferase, fazendo com que este não 
fosse traduzido para proteína; sendo assim, com esta experiência foi possível concluir que o 
gene CtsS humano é um alvo para a regulação genética mediada pelo miR-106b-5p. 
O trabalho reflectido nesta tese permitiu-nos esclarecer os alicerces principais do modelo 
inicialmente proposto: determinámos que, durante a infecção em macrófagos, M. tuberculosis 
provoca um aumento na expressão do miR-106b-5p e uma diminuição na expressão da 
catepsina S. Demonstrámos que o mRNA CtsS é um alvo para o miR-106b-5p, e que a 
redução da catepsina S durante a infecção se deve, pelo menos em parte, à acção regulatória 
do miR-106b-5p, que se encontra sobre-expresso. Deste modo contribuímos para decifrar 
parte da complexidade de mecanismos que as micobactérias do CMTB realizam para 














1.1. Tuberculosis, a past and present day health menace 
 
Tuberculosis, also known in the past as phthiasis, consumption, and the “white plague”, 
has tormented humanity for thousands of years; the oldest record of tuberculosis infecting 
human beings dates back to approximately 9000 years ago (Hershkovitz et al., 2008). From 
the 17th century up to modern age, tuberculosis was one of the main causes of death in 
Europe, and still had no cure. It came to be seen as a “romantic” disease, taking the role of a 
tragic force of fate in important works of literature such as Victor Hugo’s Les Miserábles (1862) 
and La Dame aux Camélias (1848), by Alexandre Dumas. During the 19th century, the 
tuberculosis epidemic in Europe was at its peak, holding responsibility for 25% of human 
deaths in all of Europe (Lawn and Zumla, 2011). Mycobacterium tuberculosis, the first 
identified causative agent of the disease, was discovered by Robert Koch (Koch, 1882), thus 
becoming one the first microorganisms in history to have been scientifically recognized as a 
cause of illness. Prevention against tuberculosis became increasingly effective as health and 
sanitary habits improved during the 20th century; at the same time, the death toll due to the 
disease declined during this period as new antituberculosis drugs were discovered (Lawn and 
Zumla, 2011).  
Nowadays, active tuberculosis is curable and treatable in most cases, with a 6-month 
course of antibiotics; however, despite all the advances in medicine and health management, 
tuberculosis still represents a heavy burden throughout the world, particularly in developing 
countries where access to health services is still difficult (WHO, 2013). Since 1992, the 
scientific and health-care community acknowledged the re-emergence of tuberculosis as a 
global health menace, identifying the insurgences of multidrug-resistant M. tuberculosis strains 
(MDR-TB), together with the opportunistic consortium of mycobacteria infection with HIV-AIDS, 
as the main causes of this event (1992). Currently, tuberculosis is considered by the WHO to 
be the second infectious disease, associated with a single biological agent, which causes the 
highest number of human deaths in the world, surpassed only by AIDS: in 2011, 8.7 million 
people fell ill with tuberculosis and 1.4 million died from the disease (WHO, 2012).  
 
1.2. Mycobacteria and pathogenesis 
 
Mycobacterium is a genus belonging to the phylum Actinobacteria, which comprises both 
high and low G+C containing (Ghai et al., 2012), mostly Gram-positive species. Like the 
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majority of the members of this phylum, most species of Mycobacterium are non-pathogenic, 
environmental commensals, and only small groups have evolved to exhibit pathogenicity to 
human beings and other animals (Madigan et al., 2009); even so, besides tuberculosis, other 
prestigious maladies such as leprosy and Buruli ulcer are caused by mycobacteria as well 
(Einarsdottir and Huygen, 2011; Irgens, 2002). Human tuberculosis can result from infection by 
any member of the Mycobacterium tuberculosis complex (MTC), a group of several closely 
related species, which share a common ancestor: M. tuberculosis, M. africanum, M. bovis, M. 
canettii, M. caprae, M. pinnipedii and M. microti (Aranaz et al., 2003; Ernst et al., 2007). Even 
so, approximately 95% of cases are caused by M. tuberculosis alone (Parsons et al., 2002). 
The success of MTC mycobacteria can be attributed to their ability to survive and 
proliferate inside phagocytic immune cells: they are able to avoid intracellular destruction by 
manipulating the host’s biochemical and trafficking mechanisms in a number of different ways 
(Deretic and Fratti, 1999; Wong et al., 2011). In the case of healthy, immunocompetent 
individuals, the immune response generated by the infection is generally capable of stopping 
the spread of the bacilli, containing them in histological structures called granulomas (Russell, 
2007). The presence of granulomas indicates latent infection, a situation where the person is 
infected however is healthy, and does not spread the pathogen to other people; however, 
several immune, genetic and physiological factors can trigger the progression from latent 
infection to active disease (Guzzetta and Kirschner, 2013; Leistikow et al., 2010; Tufariello et 
al., 2003). The most common and easiest form of transmission is the inhalation of airborne 
droplets containing bacilli, expelled orally by individuals whose infection has already 
progressed to active, acute pulmonary tuberculosis (Erkens et al., 2010). As such, pulmonary 
tuberculosis is the most frequent form of the disease. However, depending on the severity of 
the pulmonary infection and/or the occurrence of other less common entry points for the bacilli 
into the body, tuberculosis can be developed in other organs and body regions such as the 
central nervous system, bones and joints, lymph nodes, or even the eyes (Carrol et al., 2001). 
 
1.3. Phagocytosis and host cell factors — cathepsins  
 
The main mechanism by which professional phagocytes, such as macrophages, eliminate 
bacteria and other external particles is phagocytosis, that is, the internalization of those 
particles by enveloping them in an intracellular plasma membrane-derived compartment called 
phagosome; the phagosome then undergoes several alterations until it fuses with the 
lysosome, in a phenomenon referred to as phagosome maturation or phagolysosome 
biogenesis (Kinchen and Ravichandran, 2008). Fusion with the lysosome allows the several 
types of hydrolytic enzymes contained in the lysosome to reach the contents of the 
phagosome, thereby promoting the degradation of those contents (Coutinho et al., 2012). 
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Cathepsins are a large group of lysosomal proteases, mostly cysteine proteases, each 
with different intracellular and/or extracellular functions, such as antigen processing and 
presentation, protein degradation, bone resorption, and hormone processing (Chapman, 1998; 
Dunn et al., 1991; Kakegawa et al., 1993; Turk et al., 2000). Cysteine cathepsins, in particular, 
are among the most studied enzymes; likewise, 11 cysteine cathepsins (cathepsins B, C, F, H, 
K, L, O, S, V, X and W) have been identified in humans (Rossi et al., 2004). Moreover, recent 
studies have already demonstrated that cathepsins are manipulated by M. tuberculosis during 
macrophage infection, effectively preventing phagosome maturation, apoptosis, and antigen 
presentation (Danelishvili et al., 2011; Nepal et al., 2006; Welin et al., 2011).  
One in particular, cathepsin S, has been shown to have a critical role in antigen 
degradation and presentation in antigen-presenting cells (APCs) (Bania et al., 2003; Hsieh et 
al., 2002; Liu and Spero, 2004). Mycobacterium bovis spp. Bacille Calmette-Guérin (M. bovis 
BCG), an attenuated strain of the pathogenic M. bovis, has been shown to inhibit the 
expression of major histocompatibility complex class II (MHC class II) molecules in 
macrophages, by manipulating cathepsin S expression (Sendide et al., 2005; Soualhine et al., 




MicroRNAs (miRNAs) are a class of very small, non-coding, regulatory RNAs that exist in 
the cells of higher eukaryotes. The Central Dogma of Biology, which had been established 
since five decades ago, stated that DNA codes for RNA and RNA is translated into protein, 
thus depicting RNAs as simple intermediate molecules; as such, the discovery and 
characterization of the first miRNAs in Caenorhabditis elegans revolutionized modern thinking 
in genetics, unveiling the much more diverse and complex roles that RNA actually has (Ke et 
al., 2003; Lee et al., 1993; Reinhart et al., 2000). 
miRNAs are single-strand RNAs made of about 22 nucleotides. Newly transcribed miRNA 
precursors go through several processing steps from the moment they are transcribed to the 
moment they are mature and functional (Figure 1). Mature miRNAs, incorporated in the 
miRISC protein complex, then bind, through their “seed” sequence which comprises 7-8 
nucleotides, to a specific complementary short sequence in the 3’-UTR region of their target 
mRNA, and effectively block translation of their target gene (Ul Hussain, 2012). Research on 
miRNAs exponentially grew since about ten years ago, and is still very active and productive 
today; miRNAs are currently known to be implicated in an array of diseases, such as viral 
diseases, heart disease and, above all, cancer (Kincaid and Sullivan, 2012; Lee and Dutta, 
2009; Sun and Tsao, 2008). 
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It has also been recently reported that during mycobacteria infection in macrophages, 
some miRNAs are differentially expressed (Bettencourt et al., 2013; Singh et al., 2013; Wang 
et al., 2013). 
 
 
Figure 1. Currently accepted model for miRNA biogenesis and maturation. The miRNA precursor (pri-miRNA) is 
transcribed from the genome and is then processed by the Drosha/DGCR8 complex, originating a pre-miRNA with a 2 
nucleotide 3’ overhang. The pre-miRNA is then exported out of the nucleus via an exportin-5/Ran-GTP transmembrane 
complex; once in the cytoplasm, the pre-miRNA is further processed by the Dicer enzyme, originating a double-stranded 
RNA structure (miRNA duplex) with 2-nucleotide 3’ overhangs. One strand of the miRNA duplex is degraded and the 
other strand is assimilated into the miRNA-induced silencing complex (miRISC); miRISC is a molecular machinery 
primarily composed of proteins from the Argonaute (AGO) family and the glycine-tryptophan (GW182) protein class. The 
miRISC complex then binds to the 3’-UTR of the target mRNA with perfect or nearly perfect base complementarity, and 




The work presented in this thesis contributed to clarify a novel putative control pathway 




The first part of the thesis shall be dedicated to unraveling a connection between both the 
CtsS and miR-106b-5p genes and M. tuberculosis, in the context of macrophage infection. To 
perform this study, we explored two paths: the effect of the CtsS gene in the intracellular 
survival of mycobacteria during macrophage infection; and the effect of mycobacteria in the 
natural expression of these genes during infection. To work on the first path, macrophages with 
cathepsin gene knockdowns were infected with mycobacteria, and intracellular survival was 
assessed in each condition via CFU retrospective count. To explore the second path, RNA was 
extracted from macrophages infected with M. tuberculosis and a qRT-PCR was performed in 
order to compare miR-106b-5p gene expression in different time points post-infection; also, the 
whole cell proteins were extracted at different time points post-infection, and Western blots 
were performed to quantify cathepsin S protein expression during infection. Our findings 
provided evidence that cathepsin S negatively affects intracellular survival of mycobacteria 
during infection; also, we found that M. tuberculosis clearly up-regulates miR-106b-5p 
expression in human macrophages during infection, as opposed to the non-pathogenic M. 
smegmatis which seems to have no effect; finally, Western blot analysis revealed that the 
amount of cathepsin S is diminished during macrophage infection by M. tuberculosis. 
In the second part of this thesis, we will focus on the relationship between the miRNA 
106b-5p (miR-106b-5p) and the human cathepsin S (CtsS) gene. Based on bioinformatics 
data, we theorize that the 3´-UTR of the human CtsS gene transcript is a target for miR-106b-
5p, and as such it can suppress CtsS gene expression by blocking translation of this transcript. 
To assess these hypotheses, we constructed recombinant luciferase-producing plasmid 
expression vectors harboring a fragment of the 3’-UTR of the human CtsS gene, containing the 
seed sequence of miR-106b-5p. Luciferase activity was then analyzed between recombinant 
and non-recombinant plasmids in the presence of miR-106b-5p mimics, to draw conclusions 
about the effect of miR-106b-5p on the 3’-UTR of the human CtsS transcript. It was 
demonstrated here that miR-106b-5p has a significant affinity for the transcript; together with 
the bioinformatics analysis, this strongly enforces the hypothesis that miR-106b-5p down-
regulates post-transcriptional expression of the human CtsS gene. Altogether, these findings 
shed more light into the complex and still largely unknown mechanisms of intracellular survival 










2. Materials and methods 
 
2.1. Strains and media 
 
In this work, the mc2 155 strain of the non-pathogenic Mycobacterium smegmatis (ATCC® 
#700084™) and the H37Rv virulent strain of M. tuberculosis (ATCC® #25618™) were used to 
perform in vitro infections. As host cells in these infections, human monocyte derived 
macrophages (HMDMs) were used, as well as cells from the human acute monocytic leukemia 
cell line THP-1 (ATCC® #TIB-202™). Human peripheral blood monocytic cells (PBMCs) were 
extracted from the blood of healthy donors (courtesy of Instituto Português do Sangue, Lisbon). 
For plasmid propagation and cloning assays, the JM109 strain of Escherichia coli (ATCC® 
#53323™) was used, and all plasmid and miRNA cotransfection assays were performed on 
human cells from the HEK 293T cell line (ATCC® #CRL-3216™). 
THP-1 cells were maintained in RPMI-1640 medium supplemented with 10% HI-FBS 
(Gibco®), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM GlutaMAX™ (Gibco®), 1 mM 
sodium pyruvate (Gibco®), 1X MEM Non-Essential Amino Acids (Gibco®), and 10 mM HEPES 
(Gibco®). THP-1 cells were grown in a humid incubator at 37º C with 5% CO2, and kept at a 
concentration between 0.2 × 106 and 1.0 × 106 cells/ml.  During infection assays, THP-1 cells 
were maintained in RPMI-1640 medium supplemented as above but without Penicillin or 
Streptomycin. 
PBMCs were grown in 96-well culture plates, and maintained in RPMI-1640 medium 
supplemented with 10% HI-FBS, 2 mM GlutaMAX™, 1 mM sodium pyruvate, 50 µM of 2-
mercaptoethanol (Gibco®) and 10 mM HEPES, and grown in a humid incubator at 37% with 
5% CO2. During the differentiation process before infections, the medium was supplemented 
with 100 U/ml Penicillin and 100 μg/ml Streptomycin. 
HEK 293T cells were maintained in 10 ml of DMEM supplemented with 10% HI-FBS, 100 
U/ml penicillin, 100 μg/ml streptomycin and 2 mM GlutaMAX™. HEK 293T cells were grown in 
a humid incubator at 37º C with 5% CO2, and were routinely passed upon reaching 90-95% 
confluence. The protocol of cell passage for HEK 293T cells consisted of detaching the cells 
from the culture flask matrix by trypsinization, and diluting at 1:5 volumes in fresh 
supplemented DMEM; the trypsinization protocol used in this work consisted of removing the 
culture medium from the flask, then washing the cells by gently adding 10 ml of 1X PBS 
(Gibco®), removing the PBS, and adding 1 ml of trypsin at 500 μg/ml to the cells, tilting the 
flask to ensure that the trypsin covers the whole cell covered surface; the cells are then 
incubated at 37ºC, 5% CO2, for 5 min, to allow trypsin activity, and finally 9 ml of fresh 
supplemented DMEM are added to the cells, inactivating the trypsin. For plasmid and miRNA 
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transfection assays, HEK 293T cells were grown in DMEM supplemented as described, but 
without penicillin or streptomycin. 
E. coli cells were maintained in LB (10 mg/ml NaCl, 5 mg/ml Bacto™ Yeast Extract, 10 
mg/ml Bacto™ Tryptone for liquid LB; for solid LB, 15 mg/ml Bacto™ Agar were added to the 
liquid formula). For transformation assays, E. coli were plated in solid LB supplemented with 
100 µg/ml ampicillin and grown in a humid incubator at 37ºC. For miniprep assays, E. coli were 
maintained in liquid LB with 100 µg/ml ampicillin, and grown in an orbital shaker at 37ºC, at 140 
rpm. 
M. smegmatis cells were maintained in 7H9 broth supplemented with nutrient broth and 
glucose, each at 5 mg/ml, and M. tuberculosis cells were maintained in 7H9 broth 
supplemented with 10% BBL™ OADC Enrichment; both strains were grown in an orbital 
shaker at 37ºC and 140 rpm. For intracellular survival assays, both M. smegmatis and M. 
tuberculosis were plated in 7H10 solid broth with 10% BBL™ OADC Enrichment. 
 
2.2. Extraction of PBMCs from human blood 
 
PBMCs were extracted from buffy coats derived from the blood of healthy human donors 
through gradient centrifugation. Buffy coats were diluted 1:1 in autoMACS® Running Buffer, 
and then carefully overlaid on Ficoll-Paque™ PLUS reagent (GE Healthcare) on a 2:1 fraction, 
followed by centrifugation at 800 × g for 20 min, without acceleration or breakdown. The 
interface between the resulting two phases was recovered to a 50 ml Falcon tube, and then 
autoMACS® Running Buffer was added to make 50 ml total volume. Then it was centrifuged at 
350 × g for 5 min, the supernatant was discarded, and the pellet was resuspended in 5 ml ice-
cold autoMACS® Running Buffer; at this point, 300 μl of human CD14 MicroBeads (MACS) 
were added to the cell suspension, and the cells were incubated like this for 30 min at room 
temperature, with agitation. After, 12 ml of cold autoMACS® Running Buffer was added to the 
cell suspension, and the cells were centrifuged at 350 × g for 10 min, at 4º C. The resulting 
pellet was resuspended in 5 ml cold autoMACS® Running Buffer, and was then slowly added 
to an LS column (MACS); after all the suspension had gone through, the column was washed 
by adding 3 ml autoMACS® Running Buffer and letting it flow through, by gravity force, into the 
collector tube, two to three more times. Finally, to elute the cells bound to the column, the 
column was removed from its magnetic stand and placed on top of a new collector tube; 5 ml 
of autoMACS® Running Buffer were added to the column, and after 2 ml had gone through by 
gravity force, the remaining 3 ml were pressed through using the column plunger, eluting the 
remaining cells. Cells were then diluted 1:1 in Trypan Blue (Sigma-Aldrich) and counted in a 




2.3. In vitro macrophage infection assays 
 
In vitro infections were performed according to the same protocols for all cell types, and all 
bacterial species and strains. The infections comprised three stages: the earlier seeding of 
human cells in multiwell plates, followed by chemical activation of these cells, to induce 
differentiation of monocytic cells into macrophages; the preparation of the bacterial suspension 
to be used in the infection; and the mixing of the seeded human macrophages with the 
prepared bacteria. 
 
2.3.1.  Seeding human cells 
 
For this work, THP-1 cells were seeded in 96- or 24-well culture plates, and PBMCs were 
seeded in 24-well culture plates. The seeding/differentiation protocol lasts for 3 days and 
comprises the inoculation of a cell suspension in the wells, followed by the differentiation of 
these cells into macrophages. Cells were inoculated at 5 × 104 cells per well, for 96-well culture 
plates, or 3.0 × 105 cells per well, for 24-well culture plates.  
If working with THP-1 cells, cells are then incubated at 37ºC, 5% CO2, for 24h, with 1 ml or 
100 μl of medium (if working in 24- or 96-well plates respectively) to allow adherence to the 
bottom of the wells.  After incubating for 24h, the medium was removed from the wells and 
replaced with the same volume of medium plus 20 nM PMA (ImmunoTools); subsequently, the 
cells were again incubated as before for 24h, to allow differentiation overnight. After this 
second incubation, the cells are differentiated into macrophages and ready for infection. 
If working with PBMCs, cells are incubated at 37ºC, 5% CO2, in 400 μl of simple RPMI-
1940 medium plus 2 mM GlutaMAX™ and 10 mM HEPES, for 2 to 3 h, to starve the cells and 
allow them to better adhere to the bottom of the wells; after, 400 μl of RPMI-1640 medium plus 
20% HI-FBS, 2 mM GlutaMAX™, 200 U/ml penicillin, 200 μg/ml streptomycin, 2 mM sodium 
pyruvate, 100 µM 2-mercaptoethanol, 10 mM HEPES and 40 ng/ml MCSF (ImmunoTools) are 
gently added to each well, and the cells are incubated for 3 days to allow differentiation. Then, 
the medium is removed from the wells and replaced with 1 ml of supplemented RPMI-1640 
medium (as described in section 2.1), and the cells are again incubated for 48 h. After this 
incubation, the cells are ready for infection. 
 
2.3.2.  Preparing the bacterial suspension 
 
Prior to performing the infection, on the same day, the bacteria were collected from an 
exponential growth phase liquid culture and submitted to a protocol in order to remove traces 
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of bacterial culture medium and, above all, disperse and discard bacterial clumps. This 
procedure is the same for each bacterial strain used in infections.  
First, 10 ml of bacterial exponential growth culture are centrifuged at 3000 × g for 7 min, 
the supernatant is removed, and the pellet is resuspended in 10 ml of PBS; the suspension is 
again centrifuged as before, the supernatant is removed, and the pellet is resuspended in 5 ml 
of infection medium (specified for THP-1 cells and PBMCs in section 1.1). Following this, 
procedures are made to rid the suspension of bacterial clumps: the 5 ml of bacterial 
suspension are flushed up and down, around 20 times, with a 5 ml syringe, and the resulting 
suspension is then placed in an ultrasound bath for 5 min; finally, the suspension is centrifuged 
at low speed (350 × g) for 1 min to pellet the remaining clumps, the supernatant is transferred 
to a new recipient and the pellet is discarded; a 5 µl aliquot of the suspension is then observed 
under the microscope to confirm the absence of clumps, and after this, the bacteria are ready 
for infection.  
To determine the concentration of bacterial cells in the suspension, the OD600 of the 
suspension was read, and the suspension was subsequently diluted to achieve an OD600 of 
0.1, corresponding to 107 cells/ml, (Anes et al., 2006); after this, necessary calculations were 
made in order to achieve the desired number of bacterial cells in the desired volume of culture 
medium. 
 
2.3.3.  Infection of human macrophages in multiwell plates 
 
The infection procedure is the same for THP-1 macrophages and for HMDMs, save for the 
different culture media used in each case. 
A MOI of 10 — 10 bacteria per 1 host cell — was used in M. smegmatis infections, and a 
MOI of 1 was used in M. tuberculosis infections. When the cells were ready for infection, the 
culture medium was removed from the wells, and each well was washed once with 50 μl of 
PBS (if working with 96-well plates) or 500 μl of PBS (if working with 24-well plates); this 
washing step consists of gently adding the PBS to the wells, and removing the PBS 
immediately after, being careful not to let the cells dry or detach from the bottom of the wells. 
After washing, 50 μl or 500 μl (depending on the type of plate) of bacterial suspension were 
added to each well. Finally, after adding the bacterial suspension, the plates were incubated in 
a humid incubator at 37ºC, 5% CO2, for 1 h (for M. smegmatis infections) or 3 h (for M. 
tuberculosis infections), to allow intracellular infection. An exception to this was when the 
infected cells were to be used in downstream protein extraction and Western Blot assays; in 
these cases, because infection conditions needed to be normalized between all bacterial 
strains used to collect data from, M. smegmatis infection plates were incubated for 3 h, in the 
same way as M. tuberculosis plates. 
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After incubating, the infection medium is removed from the wells, and each well is washed 
with PBS in the same manner as above. After this, 50 μl or 500 μl of infection medium plus 10 
μg/ml gentamycin are added to each well, except for the wells that will be used in the present 
time point for downstream assays. 
 
2.4. Quantification of intracellular survival of mycobacteria after macrophage infection 
 
For this work, we used the method of CFUs determination to assess the intracellular 
survival of M. smegmatis and M. tuberculosis after macrophage infection. These assays were 
executed in different time points after in vitro infections, according to the bacterial strain or 
strains involved and their respective growth rates. CFU assays of infections with M. smegmatis 
were done 1 h and 24 h post-infection, whereas CFU assays of infections with M. tuberculosis 
were done 3 h, 24 h, 3 days, 5 days, and 7 days post-infection. 
First, the culture medium is gently and thoroughly from the wells, and then 100 μl (if 
working with 96-well plates) or 500 μl (if working with 24-well plates) of 0.05% (if performing an 
M. smegmatis infection) or 0.5% (if performing an M. tuberculosis infection) IGEPAL aqueous 
solution are added to each well, to lyse host cells and release the bacteria. The wells are then 
incubated at 37º C for 10-15 min. After this, the well contents are vigorously resuspended with 
the pipette, and serial dilutions are made from these initial suspensions. 
Finally, a 5 μl drop from each of the selected dilutions is placed on the dry surface of a 
solid agar plate (medium specifications in section 1.1), without spreading; the drops are 
allowed to dry, and are then incubated at 37º C. 
Fast growth mycobacteria such as M. smegmatis take 24-48 h to form visible colonies, 
whereas slow growth mycobacteria such as M. tuberculosis take 2 to 3 weeks. When colonies 
become visible under the microscope, they are counted, and the formula N × Df ⁄ V can be 
used to calculate the number of CFU/ml, where N = number of colonies counted, Df = dilution 
factor regarding the initial suspension, and V = volume (ml) of inoculum used (0.005 ml in this 
case). 
 
2.5. Quantification of miRNA gene expression 
 
qRT-PCRs were performed to assess gene expression during mycobacteria infection in 
macrophages. RNA was extracted from infected cells with TRIzol® Reagent (Invitrogen), 
following the reagent manufacturer’s instructions. In this work, qRT-PCRs were performed 
using the miRCURY LNA™ Universal RT microRNA PCR system (Exiqon), which contained a 
cDNA synthesis kit and an RT-PCR kit. All steps were performed according to the 
manufacturer’s instructions.  
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Complementary DNA (cDNA) was synthesized using the Universal cDNA synthesis kit II: 
volumes of reaction components (5X Reaction buffer, nuclease-free water, enzyme mix and 5 
ng/µl template RNA) were set according to the kit’s protocol; the reaction was incubated at 42º 
C for 60 min to allow cDNA synthesis, followed by 5 min at 95º C to inactivate the reverse 
transcriptase, and immediately cooled down and stored at 4º C. 
RT-PCRs were performed with the ExiLENT SYBR® Green master mix. The hsa-miR-
106b-5p LNA™ PCR primer set, UniRT (Exiqon, no.: 205884), which contained the forward 
and reverse primers, was used in this assay. Volumes of reaction components (PCR Master 
mix, PCR primer mix, and 80X diluted cDNA template) were again set according to the kit’s 
protocol. The reaction was then incubated at 95º C for 10 min to activate the polymerase and 
denature the DNA strands; this was followed by 40 amplification cycles of [DNA strand 
denaturation at 95º C, 10 s; primer annealing and amplification at 60ºC, 1min]. In the end, a 
melting curve analysis was performed to assess the specificity of the PCR primers to their 
designated targets. 
 
2.6. Analysis of the effect of cathepsin and miRNA expression during mycobacteria 
infection of macrophages 
 
2.6.1. Lentiviral infection 
 
To determine the effect of cathepsins in the intracellular survival of mycobacteria during 
macrophage infections, we used the RNAi Consortium (TRC) technology, developed by the 
Broad Institute (Cambridge, US). shRNA-producing lentiviral vectors (kindly provided by Dr. 
Luís Moita, Instituto de Medicina Molecular) were used to infect THP-1 cells and thus produce 
stable cathepsin gene knockouts in their transcriptomes. Lentiviral infection was done 
accordingly with the Broad Institute’s suggested protocol. Briefly, before infection, THP-1 cells 
were seeded in 96-well plates and differentiated into macrophages; the next day, the medium 
was removed from the wells and replaced with medium containing polybrene, and then 
lentivirus were added to the cells; the plates were then centrifuged at 800  g, 37º C, for 90 
min, to enhance infection. The medium was then removed and replaced with fresh medium 
without antibiotics, and the plates were incubated overnight at 37º C, 5% CO2. Finally, the next 
day, puromycin was added to the wells at 5 µg/µl, to eliminate uninfected cells by drug 
selection. Infected cells were grown in the appropriate culture medium (section 2.1) plus 5 






2.6.2. Transient transfection 
 
To assess the effect of cathepsin expression and miRNA intracellular presence/absence 
during mycobacteria infection in HMDMs, cells were transiently transfected with miRNA mimics 
and hairpin inhibitors, and with siRNA against cathepsin genes, using the HiPerFect® 
Transfection Reagent (QIAGEN). miRNA mimics, miRNA hairpin inhibitors, siRNA against 
cathepsin genes and all respective scramble controls  were purchased from Thermo Scientific 
Dharmacon. The protocol is identic for transfection of cathepsin gene siRNAs, miRNA mimics, 
hairpin inhibitors, and scramble controls. Cells were seeded at 3  105 per well in 24-well 
plates, and were differentiated into macrophages in the day before transfection. The next day, 
the culture medium was gently removed, cells were gently washed with 250 µl of culture 
medium without antibiotics to remove traces of antibiotic and non-attached cells; the medium 
was again removed and 200 µl of the same culture medium were added to each well. Then, for 
each well, 81 µl of simple, non-supplemented RPMI medium (RPMI (-)), 9 µl HiPerFect® 
Reagent and 10 µl of 20 µM siRNA (final siRNA concentration of 166 pM) were mixed, and the 
mixture was incubated at room temperature for 20 minutes to allow formation of transfection 
complexes. After this, 100 µl of the mixture were added to each well, dropwise and slowly, 
tilting the plate between drops to accelerate dilution and reduce the cytotoxicity of the 
transfection reagent. Cells were then incubated at 37º C, 5% CO2, for 4 to 6 h, to allow 
transfection. Finally, after incubation, 300 µl of PBMC culture medium plus 200 U/ml penicillin, 
200 μg/ml streptomycin and 40 ng/ml MCSF were added to each well, and the cells were 
incubated ta 37º C, 5% CO2, for 48 h before downstream assays. 
 
2.7. Plasmid cloning and propagation 
 
Plasmid cloning assays were performed in order to produce recombinant plasmid DNA to 
use in downstream luminescence assays. The pmirGLO Dual Luciferase miRNA Target 
Expression Vector (Promega Corporation) was used in these assays. The first step was to 
amplify the insert fragment, which will later be ligated to the plasmid vector; then both the insert 
and the vector are digested by restriction enzymes in order to create cohesive extremities, and 




Figure 2. pmirGLO vector map, and multiple cloning site (MCS). 
 
2.7.1. DNA extraction 
 
Human DNA was extracted from THP-1 cells in exponential growth phase. 10 ml of THP-1 
culture were centrifuged at 450 × g for 5 min, the culture medium was removed, and the pellet 
was resuspended in 780 µl of lysis buffer (0.1 M NaCl, 50 mM Trizma® HCl, 0.1 M EDTA, 1% 
SDS) with 0.77 mg/ml proteinase K and transferred to a 1.5 ml microtube; the tube was then 
incubated overnight at 55º C. After incubating, the lysate was mixed by inversion for 5 min, and 
then 300 µl of 5 M NaCl were added; the lysate was again mixed by inversion for 10 min, and 
then centrifuged at 16000 × g for 5 to 10 min. After, 850 µl of clean supernatant were 
transferred to a new tube, 750 µl of isopropanol were added, and the mixture was mixed by 
inversion for 2 min. The mixture was centrifuged at 16000 × g for 5 min, the supernatant was 
discarded, and the pellet was washed with ethanol at 70% (v/v); the mixture was centrifuged as 
above for 2 min, and the supernatant was carefully discarded, so as not to disturb the pellet. 
The tube was left open until the inside was completely dry, and then the pellet was detached 
and resuspended in 200 μl dH2O. Finally, making sure that the pellet has been completely 
resuspended and the DNA solution is not viscous (if so, the tube would be incubated at 55º C 
overnight, before proceeding), the OD260 nm of the solution was read to determine DNA 
concentration, and the sample was stored at -20º C. 
 
2.7.2. Insert fragment amplification 
 
A 413 bp fragment of the 3’-UTR region of the human cathepsin S (CtsS) gene, containing 
one copy of the seed sequence of miR-106b-5p (GCACTTT), was amplified by standard PCR 
(forward primer: 5’-GCGAGCTCCAAGAAATATGAAGCACTTTCTC-3’; reverse primer: 5’-
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CCCTCGAGTTTTTTGAAACAGAGTCTCCACT-3’) using the Phusion® Hot Start II DNA 
Polymerase (New England BioLabs®). Volumes and concentrations of PCR components 
(dH2O, dNTPs, 5X Phusion® HF Buffer, forward and reverse primers, DNA polymerase and 
DNA template) were set according to the enzyme manufacturer’s instructions. The PCR 
program was executed as follows: 
 
1. 1 initial polymerase activation step of:  
o 98º C — 30 s 
2. 35 denaturation/annealing/elongation cycles of: 
o 98º C — 10 s 
o 61º C — 20 s 
o 72º C — 12 s 
3. 1 last elongation step of: 
o 72º C — 5 min 
 
5 μl of PCR product mixed with 1 μl of 6X Orange DNA Loading Dye (Fermentas) were run 
in a 1.2% (m/v) agarose gel (plus 0.5 µg/ml ethidium bromide) electrophoresis (100 V, 2 h), to 
confirm the molecular mass, alongside 5 μl of O’GeneRuler 50 bp DNA Ladder (Fermentas). 
PCR products were then purified using the illustra™ GFX™ PCR DNA and Gel Band 
Purification Kit (GE Healthcare). 
 
2.7.3. Enzyme restriction 
 
Restriction reactions were performed in order to generate compatible ends between the 
insert fragments and the plasmid vector. The vector contains a multiple cloning region with 
various restriction sites (Figure 1) and, for this experiment, restriction enzymes SacI (5’-
GAGCTC-3’) and XhoI (5’-CTCGAG-3’), both from New England BioLabs®, were used. Both 
enzymes were used simultaneously in one double restriction reaction. The final reaction 
volume was 50 μl, and the quantities of the reaction components were set as follows: 
 
 0.4-1 μg purified DNA 
 20 U SacI per 1 μg DNA 
 20 U XhoI per 1 μg DNA 
 5 μl restriction enzyme buffer (10X concentrated) 
 100 μg/ml BSA 




After adding all components, they were incubated at 37º C for 1,5 h to allow restriction 
enzyme activity, and after this the reaction was stopped by incubating at 65º C for 20 min. 
Restriction products were then purified with the illustra™ GFX™ PCR DNA and Gel Band 




Ligation reactions were performed in order to ligate the DNA insert fragment to the plasmid 
vector, and thus generate recombinant plasmid DNA, necessary for downstream luminescence 
assays. T4 DNA Ligase (New England BioLabs®) was used in these reactions. The final 
reaction volume was set to 30 μl. Reaction components were set as follows: 
 110 ng plasmid vector DNA 
 180 ng insert DNA 
 3 μl T4 DNA Ligase Reaction Buffer (New England BioLabs®) 
 1 μl T4 DNA Ligase 
 Deionized, nuclease-free dH2O, up to 30 μl final reaction volume  
After adding all components, the mixture was incubated at room temperature for 30 min, 
and after that the reaction was finished. 
 
2.7.5. Plasmid propagation 
 
Vector plasmids and recombinant plasmids were transformed into and propagated in 
JM109 E. coli cells.  
JM109 cells were made chemically competent by treatment with Ca2+. 100 ml of JM109 
cell culture in exponential growth phase were chilled on ice for 15 min, and then centrifuged at 
3220 × g, 4º C, for 10 min; the pellets were resuspended in 40 ml of ice-cold 0.1 M CaCl2, and 
incubated on ice for 30 min; cells were then centrifuged as above, and each pellet was 
resuspended in 6 ml of ice-cold 0.1 M CaCl2 plus 15% UltraPure™ Glycerol (Invitrogen™). 
Cells were then stored at -80º C. 
Chemically competent cells were then transformed by heat shock treatment. Competent 
cells were thawed on ice for 10 min, and then 50 ng of plasmid DNA were added to 100 μl of 
competent cells suspension. The mixture of cells and DNA was placed in a heating block at 42º 
C for 1 min, and then immediately placed back on ice for 2 min. Then, 1 ml of LB (with no 
antibiotic) was added to the cells, and they were incubated at 37º C with agitation (140 rpm) for 
1 h; then, 100 μl of the resulting culture were spread on an LB plate with 100 μg/ml ampicillin, 
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and incubated at 37º C. Colonies were picked after 12 to 16 h of incubation, each colony was 
inoculated in 5 ml of liquid LB with 100 μg/ml ampicillin, and incubated overnight at 37º C with 
agitation; finally, each 5 ml culture was aliquoted, supplemented with 20% UltraPure™ 
Glycerol, and stored at -80º C. 
Plasmid DNA was extracted from host cells and purified for downstream assays using the 
PureLink® Quick Plasmid Miniprep Kit (Invitrogen™), following the manufacturer’s provided 
protocol. Briefly, 1 to 5 ml of liquid cell culture in exponential growth phase were centrifuged 
and resuspended in Tris-HCl (pH = 8.0) buffer with RNase A; then the kit’s lysis buffer was 
added, to allow cell lysis, and then the kit’s precipitation buffer was added to precipitate 
chromosomal DNA. This was followed by a 10 min centrifugation at 16000 × g. The 
supernatant was transferred to a spin column, briefly centrifuged at 16000 × g to bind DNA to 
the filter, the flowthrough was discarded and the DNA was washed by adding the kit’s wash 
buffer to the column and centrifuging shortly as above; finally, the DNA in the filter was eluted 
by adding dH2O to the filter and centrifuging again as above. The spin column was discarded 
and the purified plasmid DNA was stored at -20º C. 
 
2.8. Determination of miR-106b-5p effect on the 3’-UTR of the human cathepsin S gene 
transcript 
 
The effect of the human miR-106b-5p on the 3’-UTR of the human cathepsin S (CtsS) gene 
was assessed through luminescence assays, using a recombinant pmirGLO vector containing 
the 3’-UTR of the CtsS gene (further referred to as pCTSS) to produce and measure 
luminescence differences. 
Plasmids (pmirGLO non-recombinant vector and pCTSS) and miRNA mimics (miR-106b-
5p mimic and miRNA mimic scramble) were first transfected into HEK 293T cells using the 
HiPerFect® Transfection Reagent (QIAGEN). HEK 293T cells were seeded in 12-well plates, 
each well containing 2.5 × 105 cells in 1 ml culture medium, so that after 24h each well was 
approximately 80% confluent. 24 h after seeding, the transfection protocol started: 300 ng of 
plasmid DNA and 10 ng of miRNA mimic (or only plasmid DNA) were diluted in non-
supplemented DMEM to a final volume of 200 μl, for each well; 6 μl of HiPerFect® reagent 
were added to each plasmid/mimic dilution, which was then incubated at room temperature for 
10 min; then, 200 μl of culture medium were removed from each well, and 200 μl of each 
plasmid-mimic-HiPerFect® dilution was slowly added to its respective well, dropwise. The cells 
were then incubated at 37º C, 5% CO2, for 24 to 48 h, to allow transfection. 
The Dual-Luciferase® Reporter (DLR™) Assay System (Promega Corporation) was used 
to measure luciferase activity, and the assay was performed according to the manufacturer’s 
instructions. In brief, the transfected HEK 293T cells were lysed using the kit’s Passive Lysis 
27 
 
Buffer, the lysate was added to the kit’s firefly luciferase substrate, and luminescence from 
firefly luciferase activity was read immediately after, in the Tecan Infinite® M200 microplate 
reader; finally, the Renilla luciferase substrate was added, and Renilla luciferase activity was 
measured. 
 
2.9.  Quantification of cathepsin S by Western blot 
 
Cathepsin amount in human cells was assessed by Western blot. Protein samples were 
extracted from adherent cells in multiwell plates using Laemmli Sample Buffer 2X Concentrate 
(Sigma-Aldrich), diluted 1:1 in PBS. After removing the culture medium, 250 μl of Laemmli 
buffer were added to each well, resuspended with a 200 μl pipette tip to reduce viscosity, and 
then transferred to a 1.5 ml microtube; the tubes were then incubated in a heating block at 95º 
C for 5 min, and then stored at -20º C. 
20 μl of protein extract were run alongside 5 μl of NYZColour Protein Marker II (NYZTech) 
in a 12% SDS-PAGE (150 V, 400 mA) for 1 h or until the bands of the protein marker were 
widely separated from each other (running buffer: 25 mM Trizma® Base, 192 mM Glycine, 
0.1% SDS). Proteins were then transferred from the gel to a 0.45 μm nitrocellulose membrane 
(Bio-Rad) by electrophoresis (150 V, 400 mA) for 2 h (transfer buffer: 25 mM Trizma® Base, 
192 mM Glycine). The membrane was then immersed in TBS-T (15.4 mM Trizma® HCl, 137 
mM NaCl, 0.1% (v/v) Tween 20) plus 5% (m/v) of BSA and incubated at room temperature for 
15 min with angular rocking; afterwards, the membrane was incubated with Rabbit Anti-
Cathepsin S antibody (Abcam®, ref.: ab92780, diluted 1:1500) and Rabbit Anti-beta-Tubulin 
antibody (Abcam®, ref.: ab6046, diluted 1:2000), in TBS-T plus 1% (m/v) BSA, overnight, with 
angular rocking, in a 4º C refrigerated chamber. Afterwards, the membrane was washed three 
times in TBS-T with angular rocking (10 min the first time, 5 min the other two times), and was 
then incubated with Goat Anti-Rabbit IgG (H+L)-HRP Conjugate (Bio-Rad, diluted 1:5000) for 2 
h, with angular rocking. After, the membrane was washed three times, the same way as 
before, and finally 5 ml of Luminata™ Crescendo Western HRP Substrate (Millipore) were 
added to the membrane; after reacting for 5 min, luminescence was read in the ChemiDoc™ 
MP System (Bio-Rad), and later quantified using ImageJ free software. 
 
2.10. Statistical analysis 
 
Multiple group comparisons were made using one-way ANOVA tests, with SigmaPlot 11.0 
software. All prerequisites of this test were met. The adopted confidence level alpha was 
0.001, below which differences were considered significant. All analyzed experiments were 





3.1. Manipulation of cathepsin S and miR-106b-5p expression by M. tuberculosis during 
macrophage infection 
 
3.1.1. Several cathepsins are relevant for the intracellular survival of mycobacteria 
 
Previous studies have stated that lysosomal cathepsins have a role in the intracellular 
killing of mycobacteria by macrophages (Welin et al., 2011). As such, we devised an 
experimental plan to assess intracellular survival of the fast-growth, non-pathogenic M. 
smegmatis inside THP-1 macrophages with knockdowns for several different cathepsins as 
well as their respective inhibitors: THP-1 macrophages with cathepsin gene knockdowns were 
infected with M. smegmatis, and the intracellular survival of the bacteria was assessed 24 h 
post-infection. M. smegmatis is easier to manipulate than M. tuberculosis, since it has a fast 
growth rate and does not require a biosafety level 3 laboratory; other studies have also 
demonstrated M. smegmatis to be genetically quite similar to M. tuberculosis, even regarding 
some virulence genes (Altaf et al., 2010; Reyrat and Kahn, 2001), which is why we chose this 
bacterium to perform this preliminary experiment. The results show that THP-1 knockdowns for 
some cathepsins had significantly higher bacterial intracellular survival rates, indicating that 













Figure 3. Relative intracellular survival rates of M. smegmatis 24 h post-infection in THP-1 macrophages harboring 
cathepsin gene knockouts. Survival rate values were calculated as (CFUs after the experiment ÷ number of bacteria 
before the experiment) for each condition. Y-axis values were calculated as ((survival rate – mean survival rate of the 
scramble controls) ÷ standard deviation of the scramble controls). All values were divided by the mean of survival 
rates in the scramble controls as normalization. Values of Y greater than 2.5 or less than -2.5 were considered hits 
and colored red as opposed to black. Positive hits are labeled in the box on the right with their respective cathepsin 
gene knockdowns. This hit identification method was adapted from Bard et al. (2006). 
 
 
3.1.2. miR-106b-5p expression is augmented during M. tuberculosis infection, while 
cathepsin S expression in reduced 
 
It was demonstrated in our recent studies that some miRNAs are diferentially expressed 
during mycobacteria infection (Bettencourt et al., 2013). The miRDB online bioinformatics 
database at http://mirdb.org (Wang, 2008; Wang and El Naqa, 2008) predicts that the CtsS 
gene transcript is a target for miR-106b-5p, which correlates to the fact that cathepsin S was 
one of the genes identified in figure 3 that significantly reduced intracellular survival of 
mycobacteria in macrophages. As such, gene expression of miR-106b-5p was analyzed in 
human macrophages, after 24 h of infection with both M. smegmatis and M. tuberculosis via 
qRT-PCR. The results show that miR-106b-5p is significantly more expressed in cells infected 
with M. tuberculosis, comparatively with non-infected cells and cells infected with M. 
smegmatis (Figure 4).  
Following this, we assessed cathepsin quantification during macrophage infection by M. 
smegmatis or M. tuberculosis via Western blot. The results were in accordance with our 
hypothesis, as cathepsin S expression was significantly reduced 24 h post-infection with M. 
tuberculosis in human monocyte derived macrophages (HMDMs): infection with M. 
tuberculosis reduced cathepsin S expression by approximately 40%, in contrast with M. 
smegmatis which reduced cathepsin S expression by less than 10% in comparison with the 





Figure 4. miR-106b-5p gene expression in HMDMs infected with the non-pathogenic M. smegmatis (Msmeg) and 
M. tuberculosis (Mtb). Y-values are shown as (mean fold change fluorescence intensity for each bacterium – mean 






Figure 5. Relative cathepsin S expression 24 h post-infection of M. smegmatis and M. tuberculosis in HMDMs 
(Mϕs), shown by densitometry analysis. Presence of cathepsin S and β-tubulin was analyzed via Western blot. Band 
chemiluminescence was captured with the ChemiDoc™ MP System (Bio-Rad) and then quantified with ImageJ free 
software as a direct measure of band intensity. Graphic values are presented as percentage of (cathepsin band 
intensity ÷ β-tubulin band intensity), in comparison with the non-infected control. Below the chart, cathepsin S and β-






































































3.2. Influence of miR-106b-5p on cathepsin S gene translation 
 
3.2.1. miR-106b-5p reduces cathepsin S in HMDMs 
 
M. tuberculosis seems to influence miR-106b-5p expression and therefore cathepsin S 
during infection in macrophages: we verified that, during macrophage infection, M. tuberculosis 
controls cathepsin S, and also increases miR-106b-5p expression in the cell. In this way, a 
model of cathepsin S regulation via modulation of miR-106b-5p expression by M. tuberculosis 
during infection could be devised. To analyze the direct effect of miR-106b-5p on the amount of 
cathepsin S, we transfected HMDMs with miR-106b-5p mimics and assessed cathepsin S 
expression via Western blot, 24, 48 and 72 h post-transfection (Figure 6). The results indeed 
show that miR-106b-5p reduces the amount of cathepsin S, since it lowered about 40% from 
24 h to 48 h post-infection in presence of the miRNA; nonetheless, they are not very 







Figure 6. Relative cathepsin S expression in HMDMs 24, 48 and 72 h post-transfection with miR-106b-5p mimics, 
miRNA scramble (negative control) and anti-cathepsin S siRNA (positive control), shown by densitometry analysis. 
Presence of cathepsin S and β-tubulin was analyzed with Western blot. Band chemiluminescence was captured with 
the ChemiDoc™ MP System (Bio-Rad) and then quantified with ImageJ free software as a direct measure of band 
intensity. Graphic values are presented as percentage of (cathepsin band intensity ÷ β-tubulin band intensity), in 

















































3.2.2. The human cathepsin S transcript is a target for miR-106b-5p 
 
To further consolidate the hypothesis of cathepsin S regulation through miR-106b-5p 
activity, we investigated whether miR-106b-5p is able to block translation of the human CtsS 
gene transcript. To determine this, a fraction of the 3’-UTR of the CtsS gene containing the 
seed sequence of miR-106b-5p was cloned into the pmirGLO Dual Luciferase miRNA Target 
Expression Vector; afterwards, recombinant plasmids were transfected into HEK 293T cells, 
and luciferase activity was read, as a direct proportion of the miRNA-transcript association rate 
(Figure 7). The results show that there is a significant decrease in luciferase activity associated 
with the recombinant plasmid, in comparison with the non-recombinant vector, in the presence 
of miR-106b-5p mimics; hence, this represents more strong evidence in favor of our initial 







Figure 7. Flowchart scheme of the experimental plan for assessing miR-106b-5p interaction with the 3’UTR of the 
human CtsS gene transcript. A 413 bp fragment of the CtsS 3’UTR was amplified by standard PCR from human 
genomic DNA, and then digested with SacI and XhoI, along with the pmirGLO vector. The fragment was then ligated 
to the vector to originate a recombinant plasmid (pCTSS-3’UTR), with the CtsS 3’-UTR fragment inserted 
immediately downstream of the open reading frame (ORF) of the firefly luciferase gene (luc2). The recombinant 
plasmid was transfected into HEK 293T cells, along with miR-106b-5p mimics, and incubated for 24 h at 37º C, 5% 
CO2. After this, the cells were lysed, and luciferase activity was analyzed in the lysates: if there is activity, miR-106b-
5p will bind to the luc2 transcript, block translation of firefly luciferase, and ultimately prevent emission of light from 
luciferase activity; on the other hand, if there is no miRNA activity, the firefly luciferase transcript is translated, and 




Figure 8. Quantification of firefly luciferase activity in transfected HEK 293T cell lysates. Cells were transfected with 
the non-recombinant vector (pmirGLO), with the recombinant vector (pCTSS) and with the recombinant vector plus 
miR-106b-5p mimics. Values are presented as percentage of the mean of (luminescence intensity from firefly 
luciferase ÷ luminescence intensity from Renilla luciferase) ± STD, for each condition, in comparison with the 





























Tuberculosis can be seen and understood as an immunopathology: the bacterium infects 
phagocytes, and subverts their mechanisms of intracellular killing, disturbing the immune 
regulation and ultimately rendering the body susceptible to the exacerbated immunological 
response triggered by the bacterium, which in turn become the disease itself (Divangahi et al., 
2013; Rook et al., 1991). Knowledge of these matters has driven the scientific community into 
exploring possibilities of treating tuberculosis through modulation of immune system 
components, rather than using antibiotics, which are becoming increasingly less effective due 
to the various multidrug-resistant strains that arose and are currently spreading throughout the 
world. 
In the first part of this thesis, we obtained encouraging results. In the triage represented in 
Figure 3, several cathepsins were identified as influential in the intracellular killing of M. 
smegmatis, among which cathepsins D and G, which have already been shown to be relevant 
to the intracellular killing of mycobacteria (Rivera-Marrero et al., 2004; Welin et al., 2011); after 
these observations, we will need to perform the same experiment with M. tuberculosis and 
HMDMs to better establish a connection between cathepsins and mycobacterial pathogenesis 
during infection, that is, between cathepsins and the disease. Focusing on cathepsin S and 
miR-106b-5p, we also had interesting results. M. tuberculosis indeed seems to reduce 
cathepsin S expression during infection, as opposed to M. smegmatis, suggesting that 
manipulation of cathepsin S is associated with virulence in mycobacteria. Results obtained with 
miR-106b-5p expression have also been significant: M. tuberculosis up-regulates expression of 
this miRNA, again in contrast with M. smegmatis, hinting that, again, manipulation of the 
miRNA is related to mycobacterial virulence in humans. After having somewhat clarified the 
influence of M. tuberculosis in cathepsin S expression, it is necessary to explore the influence 
of the bacterium in cathepsin S function. As was stated before, recent studies have deeply 
implicated cathepsin S in antigen presentation via the major histocompatibility class II (MHC-II) 
molecules in humans (Liu and Spero, 2004; Nakagawa and Rudensky, 1999); also, it has been 
demonstrated in earlier studies that infection with M. tuberculosis causes a reduction in MHC-II 
expression in macrophages (Hmama et al., 1998). As such, the next goal for this work shall be 
to explore the correlation between M. tuberculosis infection, cathepsin S down-regulation, and 
subsequent decrease in MHC-II expression in macrophages. 
Regarding the second part of this thesis, we obtained some ambiguous results, along with 
some expressive results. Transfection assays will need to be repeated in order to confirm 
cathepsin S down-regulation in macrophages transfected with miR-106-5p mimics (Figure 6); 
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in the eventuality that these results remain the same after repeated assays, new approaches 
should be taken, such as exploring methods of increasing miR-106-5p concentration in the 
cells other than transfecting them with mimics (Jadhav et al., 2012). As for the assessment of 
miR-106b-5p effect on the human CtsS transcript, the evidence points out that indeed the 
3’UTR of CtsS is a target for miR-106b-5p regulation. However, to further consolidate this data, 
we will need to perform an affinity/specificity analysis, in addition to the affinity analysis that 
was already carried out: creating a new recombinant vector, with a 1-nucleotide mismatch in 
the seed sequence of miR-106b-5p, would allow us to understand how specific miR-106b-5p is 
to the human CtsS 3’UTR, as was described by Bettencourt et al. (2013). 
Overall, considering our initially proposed model, I can say that it was clarified and 
consolidated to a considerable extent. Still, with every new thing discovered, more questions 
arise: if M. tuberculosis really does manipulate miR-106b-5p expression during infection, what 
is the molecular/physiological mechanism behind this? Does M. tuberculosis modulate 
cathepsin S expression in any other way? Does regulation of other target genes of miR-106b-
5p interfere with the intracellular survival of M. tuberculosis? Answers to these questions would 
support and complete our hypothetic model further still (Figure 9). 
 
 
Figure 9. Our hypothesized model for cathepsin S gene (CtsS) manipulation, through modulation of miR-106b-5p, by 
M. tuberculosis during macrophage infection. The up-regulation of miR-106b-5p by M. tuberculosis during infection 
has been put to light, however the way this is processed remains unknown. Up-regulation of miR-106b seems to 
cause down-regulation of CtsS, which in turn reduces intracellular survival in M. smegmatis, in normal levels; 
however, since M. smegmatis is not pathogenic and does not reduce CtsS expression during infection, the fact that 
M. tuberculosis reduces CtsS expression during infection suggests that cathepsin S might inhibit intracellular survival 
of M. tuberculosis as well. CtsS is the first miR-106b-5p target gene to have been associated with M. tuberculosis 
infection in macrophages; however, other target genes for this miRNA might play a role in this scenario as well. 
Finally, we clarified that M. tuberculosis reduces CtsS expression during infection and that modulating miR-106b-5p 
levels seems to be a way to achieve this; still, reduction of CtsS expression during infection might be achieved 
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